Aims: The buprenorphine/naloxone (Bup/Nal)combination for the treatment of opioid dependence is available in two forms – sublingual film and tablet. Recent studies demonstrated that treatment with film leads to improved treatment retention and lower healthcare costs. In March 2013 generic tablets appeared on the market. A budget impact model was built to compare health care expenditures based on current market shares of Bup/Nal film and generic Bup/Nal tablet. (Source: Drug and Alcohol Dependence)